The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...
Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback